Yasir Khan1, Elizabeth A Brem2,3. 1. Department of Medicine, Division of Hematology/Oncology, University of California, Irvine, Irvine, CA, USA. 2. Department of Medicine, Division of Hematology/Oncology, University of California, Irvine, Irvine, CA, USA. ebrem@uci.edu. 3. Departmentof Medicine, Division of Hematology/Oncology, University of California, Irvine, Chao Family Comprehensive Cancer Center, Orange, CA, USA. ebrem@uci.edu.
Abstract
PURPOSE OF REVIEW: Diffuse large B cell lymphoma (DLBCL) is a curable and common malignancy in elderly population. Elderly patients, especially those 80 and older, have poor outcomes compared with those < 60. This may be due to the disease biology, comorbidities, and/or functional limitations. RECENT FINDINGS: Prospective data, and especially randomized data, are limited. The FIL tool objectively categorizes patients as fit, unfit, or frail. Fit and unfit patients can benefit from chemoimmunotherapy with curative intent. Evidence guiding treatment of frail patients is limited, but it appears that frail patients have similar survival regardless of treatment with curative or palliative intent. For fit and unfit patients, treatment options include rituximab with dose-attenuated CHOP or regimens with adriamycin alternatives if there is concern for cardiovascular adverse effects (AEs). Frail patients are extremely sensitive to toxicity from therapies. Frail patients and those 80 and older could greatly benefit from trials incorporating novel agents.
PURPOSE OF REVIEW: Diffuse large B cell lymphoma (DLBCL) is a curable and common malignancy in elderly population. Elderly patients, especially those 80 and older, have poor outcomes compared with those < 60. This may be due to the disease biology, comorbidities, and/or functional limitations. RECENT FINDINGS: Prospective data, and especially randomized data, are limited. The FIL tool objectively categorizes patients as fit, unfit, or frail. Fit and unfit patients can benefit from chemoimmunotherapy with curative intent. Evidence guiding treatment of frail patients is limited, but it appears that frail patients have similar survival regardless of treatment with curative or palliative intent. For fit and unfit patients, treatment options include rituximab with dose-attenuated CHOP or regimens with adriamycin alternatives if there is concern for cardiovascular adverse effects (AEs). Frail patients are extremely sensitive to toxicity from therapies. Frail patients and those 80 and older could greatly benefit from trials incorporating novel agents.
Authors: C Thieblemont; A Grossoeuvre; R Houot; F Broussais-Guillaumont; G Salles; C Traullé; D Espinouse; B Coiffier Journal: Ann Oncol Date: 2007-12-06 Impact factor: 32.976
Authors: Bertrand Coiffier; Eric Lepage; Josette Briere; Raoul Herbrecht; Hervé Tilly; Reda Bouabdallah; Pierre Morel; Eric Van Den Neste; Gilles Salles; Philippe Gaulard; Felix Reyes; Pierre Lederlin; Christian Gisselbrecht Journal: N Engl J Med Date: 2002-01-24 Impact factor: 91.245
Authors: Laurie H Sehn; Jane Donaldson; Mukesh Chhanabhai; Catherine Fitzgerald; Karamjit Gill; Richard Klasa; Nicol MacPherson; Susan O'Reilly; John J Spinelli; Judy Sutherland; Kenneth S Wilson; Randy D Gascoyne; Joseph M Connors Journal: J Clin Oncol Date: 2005-06-13 Impact factor: 44.544
Authors: S Luminari; A Montanini; D Caballero; S Bologna; M Notter; M J S Dyer; A Chiappella; J Briones; M Petrini; A Barbato; L Kayitalire; M Federico Journal: Ann Oncol Date: 2009-12-11 Impact factor: 32.976
Authors: Michael Pfreundschuh; Lorenz Trümper; Marita Kloess; Rudolf Schmits; Alfred C Feller; Christian Rübe; Christian Rudolph; Marcel Reiser; Dieter K Hossfeld; Hartmut Eimermacher; Dirk Hasenclever; Norbert Schmitz; Markus Loeffler Journal: Blood Date: 2004-03-11 Impact factor: 22.113
Authors: P Connor Johnson; Netana H Markovitz; Alisha Yi; Richard A Newcomb; Hermioni L Amonoo; Ashley M Nelson; Matthew J Reynolds; Julia Rice; Mitchell W Lavoie; Oreofe O Odejide; Ryan D Nipp; Areej El-Jawahri Journal: J Palliat Med Date: 2021-11-01 Impact factor: 2.947
Authors: Richard J Lin; Colette N Owens; Esther Drill; Augustine Iannotta; Mayan Oliveros; Dylan L Schick; Ariela Noy; John F Gerecitano; Pamela R Drullinsky; Philip C Caron; Anita Kumar; Matthew J Matasar; Craig Moskowitz; Beatriz Korc-Grodzicki; Andrew D Zelenetz; Gilles A Salles; Paul A Hamlin Journal: Haematologica Date: 2022-05-01 Impact factor: 11.047
Authors: P Connor Johnson; Alisha Yi; Nora Horick; Hermioni L Amonoo; Richard A Newcomb; Mitchell W Lavoie; Julia Rice; Matthew J Reynolds; Christine S Ritchie; Ryan D Nipp; Areej El-Jawahri Journal: Oncologist Date: 2021-08-12 Impact factor: 5.837